Umbilical Cord Blood Proteomic Analysis and Neonatal Brain Injury
| Status: | Completed |
|---|---|
| Conditions: | Neurology |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 4/21/2016 |
| Start Date: | October 2005 |
| End Date: | December 2008 |
The investigators propose to compare the proteomic analysis of umbilical venous blood from
neonates with brain injury to gestational age matched noninjured controls. After delivery an
umbilical arterial gas and a 10 ml umbilical venous sample are obtained, then the remainder
of the cord blood is discarded. The investigators plan to use this cord blood that would
otherwise be discarded to perform our proteomic analysis. The investigators will use up to
20 ml of cord blood per delivery. This will be a 5 year study during which time the
investigators hope to analyze 450 infants at Johns Hopkins Hospital and Bayview Medical
Center. The investigators will obtain an umbilical venous sample from infants born at < 34
weeks gestation. For infants born at > 34 weeks the investigators will obtain an umbilical
venous sample for any infant suspected to be at risk for neurologic injury by having a
diagnosis of chorioamnionitis during labor, nonreassuring fetal heart rate tracing at the
time of delivery, or a 5 minute Apgar < 7. For the infants born at < 34 weeks the brain
injured infants will be compared to gestational age matched controls without brain injury.
For the infants born at > 34 weeks, each infant later confirmed to have neurologic morbidity
will be compared to a gestational age matched noninjured control. The investigators hope to
use proteomic analysis to determine if there are measurable differences in protein
expression between the 2 groups.
neonates with brain injury to gestational age matched noninjured controls. After delivery an
umbilical arterial gas and a 10 ml umbilical venous sample are obtained, then the remainder
of the cord blood is discarded. The investigators plan to use this cord blood that would
otherwise be discarded to perform our proteomic analysis. The investigators will use up to
20 ml of cord blood per delivery. This will be a 5 year study during which time the
investigators hope to analyze 450 infants at Johns Hopkins Hospital and Bayview Medical
Center. The investigators will obtain an umbilical venous sample from infants born at < 34
weeks gestation. For infants born at > 34 weeks the investigators will obtain an umbilical
venous sample for any infant suspected to be at risk for neurologic injury by having a
diagnosis of chorioamnionitis during labor, nonreassuring fetal heart rate tracing at the
time of delivery, or a 5 minute Apgar < 7. For the infants born at < 34 weeks the brain
injured infants will be compared to gestational age matched controls without brain injury.
For the infants born at > 34 weeks, each infant later confirmed to have neurologic morbidity
will be compared to a gestational age matched noninjured control. The investigators hope to
use proteomic analysis to determine if there are measurable differences in protein
expression between the 2 groups.
We will draw up to 20 ml of umbilical venous blood at the time of delivery from infants born
at < 34 weeks gestation, and for any infant born at > 34 weeks suspected to be at risk for
neurologic morbidity by having intrapartum chorioamnionitis, nonreassuring fetal heart
tracing prior to delivery, or a 5 minute Apgar < 7. For each infant born at > 34 weeks later
confirmed to have neurologic morbidity by head ultrasound or EEG we will draw cord blood
from a gestational age matched control without intrapartum infection or nonreassuring fetal
heart tracing prior to delivery. At the time of delivery an umbilical arterial gas and
umbilical venous sample for a type and screen, RPR and hematocrit are routinely drawn. The
remainder of the cord blood is discarded. After the routinely done arterial blood gas and
umbilical venous blood sample are obtained the remainder of the umbilical cord blood, which
would otherwise be discarded, will be collected using a 23 gauge or larger needle into a
heparinized tube. The sample will be centrifuged for 10 minutes and the plasma layer
separated. The sample will be placed into 1.5 ml eppendorf tubes in 500 ul aliquots.
Proteomic techniques including mass spectrometry, 2-dimensional electrophoresis, and
chromatography, will be used to analyze the proteome from the brain injured and control
groups. Specific proteins will be identified, and differences in expression compared between
the 2 groups.
at < 34 weeks gestation, and for any infant born at > 34 weeks suspected to be at risk for
neurologic morbidity by having intrapartum chorioamnionitis, nonreassuring fetal heart
tracing prior to delivery, or a 5 minute Apgar < 7. For each infant born at > 34 weeks later
confirmed to have neurologic morbidity by head ultrasound or EEG we will draw cord blood
from a gestational age matched control without intrapartum infection or nonreassuring fetal
heart tracing prior to delivery. At the time of delivery an umbilical arterial gas and
umbilical venous sample for a type and screen, RPR and hematocrit are routinely drawn. The
remainder of the cord blood is discarded. After the routinely done arterial blood gas and
umbilical venous blood sample are obtained the remainder of the umbilical cord blood, which
would otherwise be discarded, will be collected using a 23 gauge or larger needle into a
heparinized tube. The sample will be centrifuged for 10 minutes and the plasma layer
separated. The sample will be placed into 1.5 ml eppendorf tubes in 500 ul aliquots.
Proteomic techniques including mass spectrometry, 2-dimensional electrophoresis, and
chromatography, will be used to analyze the proteome from the brain injured and control
groups. Specific proteins will be identified, and differences in expression compared between
the 2 groups.
Inclusion Criteria:
- Less than 34 weeks gestational age or more than 34 weeks with a risk factor for brain
injury such as chorioamnionitis, nonreassuring fetal heart rate tracing, metabolic
acidosis, or hypotonia at birth.
Exclusion Criteria:
- Major congenital or chromosomal abnormalities in fetus
We found this trial at
1
site
Johns Hopkins Hospital Patients are the focus of everything we do at The Johns Hopkins...
Click here to add this to my saved trials
